Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

Brainomix and Endeavor BioMedicines have presented positive phase 2a clinical trial results using quantitative image analysis to evaluate treatment for Idiopathic Pulmonary Fibrosis (IPF). This advancement improves the ability to measure disease progression and treatment response.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ ◆ The Wire takeaway

You can now deploy advanced imaging analytics to improve trial endpoints in pulmonary diseases, accelerating validation of new treatments and cutting development timelines.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Digital Healthipfclinical-trialimage-analysisdigital-healthpulmonary-fibrosis